WCLC 2025 - Posters & ePosters-P3.18.60 The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) Network: A Nationwide Consortium to Improve Lung Cancer Outcome

P3.18.60 The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) Network: A Nationwide Consortium to Improve Lung Cancer Outcome

Back to course

Pdf Summary

The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) research network, funded by the French National Cancer Institute (2024-2029), is a nationwide multidisciplinary consortium aimed at improving therapeutic management and outcomes for patients with lung adenocarcinoma harboring targetable genetic alterations such as EGFR, ALK, ROS1, BRAF, and KRAS. Despite advances in targeted therapies, long-term disease control remains challenging due to therapeutic resistance and variable patient responses linked to tumor molecular characteristics and other factors.<br /><br />COALA brings together 15 teams from university hospitals, cancer centers, research institutes, and associated partners across France, with a budget of 3 million euros over five years. The consortium’s integrated research program combines clinical, biological, computational, and sociological expertise to understand tumor behavior, improve personalized treatments, prevent resistance, and ultimately aim for cure rather than short-term remission.<br /><br />Key methodological innovations include the integration of multiomic data (e.g., spatial proteomics, transcriptomics, single-cell sequencing), advanced molecular analyses, mathematical modeling, and AI-driven approaches to develop deep tumor phenotyping from limited data. Experimental models such as patient-derived xenografts (PDX), genetically engineered mouse models (GEMM), organoids, and diverse assays like ddPCR and Ribo-seq are central tools. A user-friendly data interrogation platform will also be developed to facilitate broad access to complex datasets.<br /><br />COALA’s mission is to leverage this multidisciplinary and integrated approach to extend therapeutic benefits for good responders, enhance efficacy in poor responders, and address the emergence of therapeutic resistance in oncogene-addicted lung cancer. Coordinated by Professor Julien Mazières at CHU Toulouse, the network emphasizes translational research and dissemination of cutting-edge knowledge to transform standard of care and move toward cure in this challenging cancer subtype.

Asset Subtitle

Julien Mazieres

Meta Tag

Speaker Julien Mazieres

Topic Clinical Trials in Progress

Keywords

COALA research network

lung adenocarcinoma

targetable genetic alterations

EGFR

ALK

ROS1

BRAF

KRAS

therapeutic resistance

multiomic data integration